QTI

QT Imaging Holdings, Inc. (QTIH) - Q1 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025. QT Imaging Holdings, Inc. is a medical device company developing and commercializing the QT Breast Scanner, a low-frequency sound wave imaging system. The Company is classified as a smaller reporting company and an emerging growth company. Following a Nasdaq delisting in January 2025, the Company's common stock trades on the OTCQB Venture Market under the symbol "QTIH."

Key Financial Metrics

Note: Total Debt excludes Related Party Notes Payable of $3,848,725 which are classified separately on the balance sheet.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 105% year-over-year, driven by the sale of six QT Breast Scanners in Q1 2025 compared to three in Q1 2024, supported by Minimum Order Quantities (MOQs) in the amended distribution agreement with NXC Imaging.
• Operating Expenses: Total operating expenses decreased 55% to $2.85 million, primarily due to a $3.9 million reduction in transaction expenses compared to the prior year.
• Net Loss Expansion: Net loss widened significantly to $11.1 million (from $0.6 million) due to non-cash charges, including a $6.6 million loss on the issuance of the Lynrock Lake Term Loan and a $2.0 million debt extinguishment loss.
• Debt Restructuring: The Company secured a $10.1 million senior secured term loan (Lynrock Lake) and used proceeds to fully settle the Yorkville Note and Cable Car Note, significantly reducing current maturities of long-term debt.
• Warrant Liability: The warrant liability increased to over $20 million due to the issuance of new warrants to Lynrock Lake and Yorkville in connection with the debt restructuring.

Outlook, Risks, and Management Commentary

• Liquidity and Capital Resources: Management believes cash on hand, proceeds from the Lynrock Lake Term Loan, and recent PIPE investments (April and May 2025) are sufficient to fund operations for at least the next 12 months. The Company expects to continue incurring losses until revenues support the cost structure.
• Strategic Agreements: The Company entered into a manufacturing agreement with Canon Medical Systems to scale production and an amended distribution agreement with NXC Imaging, projecting potential cash inflows of $18.0 million in 2025 and $27.0 million in 2026.
• Key Risks:
  • Going Concern: The Company has an accumulated deficit of $43.1 million and relies on future financing and revenue growth to sustain operations.
  • Customer Concentration: 98% of Q1 2025 revenue was derived from a single customer (NXC Imaging).
  • Dilution: Significant dilution is expected from outstanding warrants (over 104 million shares) and potential future equity issuances.
  • Debt Covenants: The new Lynrock Lake Term Loan includes restrictive covenants, including mandatory prepayments from extraordinary receipts and asset sales.
• Subsequent Events: In April and May 2025, the Company completed and entered into agreements for PIPE investments totaling approximately $700,000 to fund working capital.

Investor Verification Checklist

• Debt Covenants: Verify the specific triggers for mandatory prepayments under the Lynrock Lake Term Loan and the impact on future cash flows.
• Warrant Liability Volatility: Assess the sensitivity of the $20.2 million warrant liability to changes in the Company's stock price, as fluctuations directly impact net income.
• Customer Dependency: Confirm the stability of the NXC Imaging distribution agreement and the enforceability of the Minimum Order Quantities (MOQs).
• Manufacturing Capacity: Validate the operational readiness of the Canon Medical Systems manufacturing partnership to meet projected demand.
• Related Party Transactions: Review the terms of the $3.8 million related party notes payable and the recent PIPE investments from directors.